As for the fourth quarter of FY17, Sutlej earned Rs 612.03 crore, recording a 9.03 per cent increase from Rs 561.32 crore in Q4 FY16.
The board of directors of the company has recommended dividend of Rs 13 per equity share for the year ended March 2017. It also considered and approved the sub-division of each of the equity shares of the company presently having a face value of Rs 10, into 10 equity shares having a face value of Re 1 each.
The board has also given its approval for raising Rs 500 by borrowing for long term working capital requirements and the company's growth plan.
"The challenging domestic business environment continued post demonetisation well into Q4 of FY2017. The industry did start witnessing a slow revival of demand along with increase in raw material prices towards the end of Q4. Strong foreign currency inflows and the consequential strengthening of INR has put a dampener on exports creating more uncertainty. It is expected that margins would continue to be under pressure during H1 of 2018," said CS Nopany, executive chairman, Sutlej Textiles and Industries Ltd. (KD)
Fibre2Fashion News Desk – India
Textiles | On 19th Jul 2018
Kenya will use a Sh6 billion loan from India’s Exim Bank to expand...
Apparel/Garments | On 19th Jul 2018
Vietnam is among the world's five biggest textile exporters and...
Fashion | On 19th Jul 2018
Adidas Originals has launched its newest silhouette, P.O.D. System,...
Textile & apparel bodies
The mid-term review of FTP is progressive, growth oriented
Balavigna Weaving Mills Pvt Ltd
The biggest challenge that the weaving industry faces is high price
Dolphin Jingwei Machines
Taxation policies need to be made simpler
<div>New Delhi-based Brinjal Designs Pvt Ltd manufactures home furnishing...
Established in 1956 with a small beginning, Embee today manufactures a...
<div><b>Liz Manning</b>, Business Development Manager at Catexel, has...
Giorgio Mantovani, MD of Corman, with a presence in both Milano and New...
Biovation II LLC
Kerem Durdag, CEO, Biovation II LLC, provides an insight into future...
Kevin Nelson, Chief Scientific Officer, TissueGen discusses the growing...